Triflusal
CAY-30274-25 25 mg
CAS
322-79-2
Formulation
A crystalline solid
Purity
≥98%
MW
248,155389
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A platelet aggregation inhibitor (IC50s = 48.3 and 693 µM in isolated human whole blood and platelet-rich plasma, respectively); inhibits arachidonic acid-induced TXB2 and PGF1α production (IC50s = 468 and 339 µM, respectively); decreases IgG-ovalbumin immune complex-induced NF-κB nuclear translocation and NO production in isolated rat peritoneal macrophages at 1,000 µM; reduces infarct volume and peri-infarct levels of OX-6 in a rat model of focal ischemia induced by permanent MCAO at 30 mg/kg; reduces increases in APP levels induced by amyloid-β (25-35) in rats at 30 mg/kg
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
